Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: May 19, 2008
Last updated: March 19, 2015
Last verified: March 2015
Approximately 45 hyperphosphatemic CKD patients not on dialysis will be entered into this study at approximately 20 sites within Europe and 5-10 in Australia. The purpose of this study is to determine if sevelamer carbonate tablets dosed three times a day (TID) is an effective treatment for the control of serum phosphorous levels in hyperphosphatemic CKD patients not on dialysis. Total length of participation is approximately 14 weeks.

Condition Intervention Phase
Chronic Kidney Disease
Drug: Sevelamer carbonate (Renvela®)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Dose Titration of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not On Dialysis

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Evaluate the efficacy of sevelamer carbonate tablets dosed three times per day (TID) with meals on control of serum phosphorus levels [ Time Frame: Up to day 70 ]
  • Evaluate the safety and tolerability of sevelamer carbonate tablets dosed TID with meals. [ Time Frame: Up to day 70 ]

Secondary Outcome Measures:
  • Serum calcium-phosphorus product [ Time Frame: Up to day 70 ]
  • Serum lipid profile [total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol] [ Time Frame: Up to day 70 ]
  • Percent responders [serum phosphorus between 2.7 and 4.6 mg/dL (0.87 and 1.49 mmol/L) inclusive] at Day 56/ET [ Time Frame: Up to day 70 ]

Enrollment: 49
Study Start Date: January 2006
Study Completion Date: March 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Sevelamer Carbonate Tablets Dosed Three Times A Day
Drug: Sevelamer carbonate (Renvela®)
Sevelamer Carbonate Tablets Dosed Three Times A Day


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A minimum of 120 male and female patients with chronic kidney disease not requiring dialysis will be screened for participation in the study.
  • Men or woman 18 years of age or older
  • If currently taking phosphate binder(s), willing to stop this and enter a 2 week washout period
  • Willing to avoid any intentional changes in diet such as fasting or dieting
  • Have the following central laboratory measurements: 1. If not on a phosphate binder, a serum phosphorus measurement ≥ 5.5 mg/dL (1.76 mmol/L) at Screening (Visit1). 2. If taking a phosphate binder(s) at screening, a serum phosphorus measurement ≥ 5.5 mg/dL (1.76 mmol/L) after the two-week washout period at Visit 1a (Day 0).
  • At Screening (Visit 1), have the following central laboratory measurements: 1. 25-hydroxyvitamin D ≥ 10 ng/mL 2. iPTH ≤ 800 pg/mL
  • Willing and able to take sevelamer carbonate alone as a phosphate binder for the duration of the study
  • Willing and able to maintain screening doses of lipid medication, 1,25 dihydroxyvitamin D, and/or cinacalcet for the duration of the study, except for safety reasons
  • Willing and able to avoid antacids and phosphate binders containing aluminum, magnesium, calcium or lanthanum for the duration of the study unless prescribed as an evening calcium supplement
  • If female and of childbearing potential (pre-menopausal and not surgically sterile), willing to use an effective contraceptive method throughout study, which includes barrier methods, hormones, or IUDs
  • Expecting not to initiate dialysis for the duration of this study
  • Considered compliant with phosphate binders (if applicable)
  • Willing and able to provide informed consent
  • Has not participated in any other investigational drug studies within 30 days prior to enrollment,
  • Level of understanding and willingness to cooperate with all visits and procedures as described by the study personnel

Exclusion Criteria:

  • Active bowel obstruction, dysphagia, swallowing disorder or severe gastrointestinal (GI) motility disorders
  • Active ethanol or drug abuse, excluding tobacco use
  • Use of anti-arrhythmic or anti-seizure medications for arrhythmia or seizure disorders.
  • In the opinion of the investigator, patient has poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, HIV infection, or any clinically significant unstable medical condition
  • Pregnant or breast-feeding
  • Evidence of active malignancy except for basal cell carcinoma of the skin
  • Unable to comply with the requirements of the study
  • Known hypersensitivity to sevelamer or any constituents of the study drug
  • Any other condition, which in the opinion of the investigator will prohibit the patient's inclusion in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00681941

Australia, Queensland
Nephrology Department, Princess Alexandra Hospital
Wooloongabba, Queensland, Australia, 4102
Australia, South Australia
Renal Unit, The Queen Elizabeth Hospital
Woodville, South Australia, Australia, 5011
Australia, Tasmania
Renal Research Unit, Launceston General Hospital
Launceston, Tasmania, Australia, 7250
Australia, Victoria
The Royal Melbourne Hospital, Department of Nephrology
Parkville, Victoria, Australia, 3050
Melbourne Renal Research Group, Epworth Medical Centre
Richmond, Victoria, Australia, 3121
Nyremedicinsk Afdeling, Medicinerhuset
Aalborg, Denmark, DK-9100
Nefrologisk Afdeling, Hilleroed Sygehus
Hilleroed, Denmark, DK 3400
Medicinsk Afdeling
København, Denmark, DK-2100
Medicinsk Afdeling, nefrologisk, Roskilde Sygehus
Roskilde, Denmark, DK-4000
George Pompidou, European Hospital
Paris, France, 75908
Universitätsklinikum Aachen, Medizinsche Klinik II
Aachen, Germany, D-52074
Universitätsklinikum Hamburg Eppendorf
Hamburg, Germany, D-20246
Heidelberg, Germany, D-69115
KfH Nierenzentrum
Nürnberg, Germany, D-90431
Stadt Klinken Solingen, Klinik für Nephrologie und Allgemeine Innere Medizin
Solingen, Germany, D 42653
Nephrologisches Zentrum
Villingen-Schwenningen, Germany, D 78054
United Kingdom
Birmingham Hospital, Queen Elizabeth Medical Centre
Birmingham, England, United Kingdom, B15 2PR
Southmead Hospital
Bristol, England, United Kingdom, BS10 5NB
Addenbrooke's Dialysis Centre
Cambridge, England, United Kingdom, CB2 2QQ
Leicester General Hospital
Leicester, England, United Kingdom, LE5 4PW
Renal Department, The Royal London Hospital
London, England, United Kingdom, E1 1BB
Renal & Urology SDU Offices
London, England, United Kingdom, SE1 9RT
Renal Dialysis Unit, Manchester Royal Infirmary
Manchester, England, United Kingdom, M13 9WL
Department of Renal Medicine, Hope Hospital
Manchester, England, United Kingdom, M6 8HD
Renal Unit, Queen Alexandra Hospital
Portsmouth, England, United Kingdom, PO6 3RY
Sponsors and Collaborators
Genzyme, a Sanofi Company
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

Responsible Party: Medical Monitor, Genzyme Corporation Identifier: NCT00681941     History of Changes
Other Study ID Numbers: SVCARB00105
Study First Received: May 19, 2008
Last Updated: March 19, 2015

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Phosphorus Metabolism Disorders
Metabolic Diseases
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 21, 2017